Partial
Mostly Aligned
Patient Risk:
Info
Summary
Several label-supported statements (composition, adjunct to diet/exercise, adult T2DM glycemic control, mechanism class for each ingredient) align with the provided label excerpts. However, several claims are not supported by the provided excerpts, and some exclusivity/status/patent timing claims are outside what the label provides.
Category Scores
Accurate Statements
Glyxambi contains linagliptin.
Label text: GLYXAMBI is a combination of empagliflozin and linagliptin (Indications and Usage); and Mechanism of Action lists linagliptin as a DPP-4 inhibitor (12.1).
Linagliptin is a DPP-4 inhibitor.
Label text: GLYXAMBI contains linagliptin, a DPP-4 inhibitor (12.1).
Glyxambi contains empagliflozin.
Label text: GLYXAMBI is a combination of empagliflozin and linagliptin (Indications and Usage); and Mechanism of Action lists empagliflozin (12.1).
Empagliflozin is an SGLT-2 inhibitor.
Label text: GLYXAMBI contains empagliflozin, a SGLT2 inhibitor (12.1).
Glyxambi is approved to improve glycemic control in adults with type 2 diabetes mellitus.
Label text: GLYXAMBI indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1 Indications and Usage).
Glyxambi is taken alongside diet and exercise.
Label text: indicated as an adjunct to diet and exercise to improve glycemic control (1 Indications and Usage).
Unsupported Statements
The FDA granted approval for Glyxambi on May 20, 2015.
Not present in the provided label excerpts.
Glyxambi received standard FDA approval.
Not stated in the provided label excerpts.
No accelerated FDA status was noted for Glyxambi.
Not stated in the provided label excerpts.
No priority FDA status was noted for Glyxambi.
Not stated in the provided label excerpts.
The main patent covering the linagliptin-empagliflozin combination expires in 2029.
Not stated in the provided label excerpts.
The brand name Glyxambi is expected to have about 14 years of exclusivity from its 2015 launch.
Not stated in the provided label excerpts.
Contradictions
Important Omissions
Limitations of use for glycemic control: not recommended for type 1 diabetes mellitus and not recommended for adults with type 2 diabetes mellitus with eGFR < 30 mL/min/1.73 m^2.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Unsupported claims relate to approval/exclusivity/patent timing rather than clinical use. The only material potential risk from label misalignment would be if the omission of limitations of use were acted upon; however, the provided claims largely focus on indication and composition.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims (FDA approval date/status, patent expiration, and exclusivity duration) are not supported by the supplied label excerpts.
Suggested Improvement
Limit statements to the content present in the provided label (e.g., composition, mechanism, and the labeled indication with adjunct diet/exercise; avoid or qualify approval/exclusivity/patent timing claims unless supported by label-provided regulatory history or other provided documents). Also include labeled limitations of use when describing the indication broadly.